Roche: positive data in liver cancer
(CercleFinance.com) - Roche announces positive data for the imbrave150 phase III study, evaluating Tecentriq, in combination with Avastin, as treatment for unresectable hepatocellular carcinoma in patients who have not previously received systemic therapy.
The study achieved its co-primary endpoints by demonstrating a statistically and clinically significant improvement in overall survival and progression-free survival, compared with the sorafenib standard of care.
This data in the treatment of the most common form of liver cancer will be submitted to health authorities around the world, including the US FDA, the European Medicines Agency and the National Administration of Medical Products of China.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The study achieved its co-primary endpoints by demonstrating a statistically and clinically significant improvement in overall survival and progression-free survival, compared with the sorafenib standard of care.
This data in the treatment of the most common form of liver cancer will be submitted to health authorities around the world, including the US FDA, the European Medicines Agency and the National Administration of Medical Products of China.
Copyright (c) 2019 CercleFinance.com. All rights reserved.